Thermo Fisher Scientific TMO
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Thermo Fisher Scientific (TMO) Business Model and Operations Summary
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
Key Insights
Thermo Fisher Scientific (TMO) Core Market Data and Business Metrics
Latest Closing Price
$482.97Market Cap
$181.82 BillionPrice-Earnings Ratio
29.22Total Outstanding Shares
377.26 Million SharesTotal Employees
125,000Dividend
$0.43 Per Share QuarterlyIPO Date
August 27, 1980SIC Description
Measuring & Controlling Devices, NecPrimary Exchange
New York Stock ExchangeHeadquarters
168 Third Avenue, Waltham, MA, 02451
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $-6.79 Billion |
| Net Cash Flow From Investing Activities | $-5.84 Billion |
| Net Cash Flow | $-3.97 Billion |
| Net Cash Flow From Operating Activities | $8.67 Billion |
| Net Cash Flow From Operating Activities, Continuing | $8.67 Billion |
| Net Cash Flow From Financing Activities | $-6.79 Billion |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Selling, General, and Administrative Expenses | $8.60 Billion |
| Income/Loss From Equity Method Investments | $-42 Million |
| Income Tax Expense/Benefit, Deferred | $-1.21 Billion |
| Research and Development | $1.39 Billion |
| Income/Loss From Continuing Operations Before Tax | $7.04 Billion |
| Benefits Costs and Expenses | $35.84 Billion |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $6.86 Billion |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $-4 Million |
| Comprehensive Income/Loss | $6.86 Billion |
| Other Comprehensive Income/Loss | $520 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Parent | $49.58 Billion |
| Inventory | $4.98 Billion |
| Wages | $1.99 Billion |
| Long-term Debt | $31.07 Billion |
| Temporary Equity | $120 Million |
| Fixed Assets | $9.31 Billion |
Historical Dividends
Current dividend: $0.43 Per Share Quarterly
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| Feb 19, 2025 | Apr 15, 2025 | Mar 14, 2025 | $0.43 | Quarterly |
| Nov 7, 2024 | Jan 15, 2025 | Dec 13, 2024 | $0.39 | Quarterly |
| Jul 11, 2024 | Oct 15, 2024 | Sep 13, 2024 | $0.39 | Quarterly |
| May 22, 2024 | Jul 15, 2024 | Jun 14, 2024 | $0.39 | Quarterly |
| Feb 21, 2024 | Apr 15, 2024 | Mar 15, 2024 | $0.39 | Quarterly |
| Nov 9, 2023 | Jan 16, 2024 | Dec 15, 2023 | $0.35 | Quarterly |